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Abstract
A cross-sectional study was performed to assess bone health history among aromatase inhibitor (AI) users before breast
cancer (BC) diagnosis, which may impact fracture risk after AI therapy and choice of initial hormonal therapy. A total of 2,157
invasive BC patients initially treated with an AI were identified from a prospective cohort study at Kaiser Permanente
Northern California (KPNC). Data on demographic and lifestyle factors were obtained from in-person interviews, and bone
health history and clinical data from KPNC clinical databases. The prevalence of osteoporosis and fractures in
postmenopausal AI users was assessed, compared with 325 postmenopausal TAM users. The associations of bone health
history with demographic and lifestyle factors in AI users were also examined. Among all initial AI users, 11.2% had a prior
history of osteoporosis, 16.3% had a prior history of any fracture, and 4.6% had a prior history of major fracture.
Postmenopausal women who were taking TAM as their initial hormonal therapy had significantly higher prevalence of prior
osteoporosis than postmenopausal AI users (21.5% vs. 11.8%, p,0.0001). Among initial AI users, the associations of history
of osteoporosis and fracture in BC patients with demographic and lifestyle factors were, in general, consistent with those
known in healthy older women. This study is one of the first to characterize AI users and risk factors for bone morbidity
before BC diagnosis. In the future, this study will examine lifestyle, molecular, and genetic risk factors for AI-induced
fractures.
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Introduction
Aromatase inhibitors (AI) have been replacing tamoxifen (TAM)
as adjuvant hormonal therapy for postmenopausal women
diagnosed with early stage, hormone receptor (HR)-positive breast
cancer. The current third-generation AIs inhibit 96–99% in vivo
aromatase enzyme activity [1], thereby decreasing endogenous
estrogen levels far below levels from natural menopause [2]. This
highly efficient estrogen depletion by AIs benefits breast cancer
patients by extending recurrence-free survival superior to TAM
[3,4,5]. However, AIs put patients at high risk of fractures due to
the central role of estrogen in maintaining normal bone
metabolism [6]. In contrast, TAM is generally believed to be
bone-conserving [2]. Several expert groups have developed
guidelines for evaluating fracture risk in breast cancer patients
who are planning to start AI therapy [7,8,9,10], so that the benefits
and harms of AIs can be carefully assessed to make an educated
decision on choice of hormonal therapy.
The aforementioned guidelines vary slightly but usually include
bone mineral density (BMD) testing and clinical assessment of risk
factors for fracture [7,8,9,10]. Although BMD remains a strong
predictor for fracture risk, several studies have shown that a large
proportion of patients who experienced fragility fractures had T-
scores in the non-osteoporotic range [11,12], which highlights the
importance of evaluation of BMD-independent risk factors, such
as a priori bone health history, age, physical activity, smoking, and
alcohol intake [13,14]. However, to our knowledge, only a few
small studies have examined bone health history among AI users
prior to breast cancer diagnosis [15,16], and no studies have
investigated lifestyle factors and prior risk of fracture in this patient
population. In a real-world clinical setting, it is unknown how bone
health history would affect hormonal therapy choice among
postmenopausal women with HR-positive breast cancer. These
data will be important to inform treatment and prevention
strategies for AI users as a high-risk population for bone morbidity.
Furthermore, it is of clinical significance to also examine whether
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Table 1. Baseline characteristics of study cohort by initial use of aromatase inhibitor (AI) or tamoxifen (TAM).
Overall Postmenopausal Only
AI (Initial Use) AI (Initial Use) TAM (Initial Use) p value1
n=2157 n=2033 n=325
n (%) n (%) n (%)
Age at Breast Cancer (BC) Diagnosis (years) ,0.0001
,50 80 (3.7) 28 (1.4) 47 (14.5)
50–59 640 (29.7) 581 (28.6) 101 (31.1)
60–69 891 (41.3) 883 (43.4) 99 (30.5)
$70 546 (25.3) 541 (26.6) 78 (24.0)
Mean (SD) 64.4 (9.1) 65.2 (8.5) 62.0 (11.2)
Menopausal Status –
Premenopausal 118 (5.5) 0 (0) 0 (0)
Postmenopausal 2033 (94.5) 2033 (100) 325 (100)
AJCC Stage at BC Diagnosis 0.0003
I 1165 (54.0) 1120 (55.1) 218 (67.1)
II 751 (34.8) 693 (34.1) 85 (26.2)
III 206 (9.6) 187 (9.2) 20 (6.2)
IV 35 (1.6) 33 (1.6) 2 (0.6)
Race/Ethnicity 0.62
White 1541 (71.4) 1467 (72.2) 222 (68.3)
African American 124 (5.8) 115 (5.7) 22 (6.8)
Asian 221 (10.3) 202 (9.9) 31 (9.5)
Hispanic 225 (10.4) 205 (10.1) 43 (13.2)
Other 46 (2.1) 44 (2.2) 7 (2.2)
BMI (kg/m2) ,0.0001
,25 642 (30.0) 595 (29.5) 127 (39.4)
25–29.9 680 (31.8) 645 (31.9) 108 (33.5)
$30 816 (38.2) 780 (38.6) 87 (27.0)
Mean (SD) 29.0 (6.5) 29.0 (6.5) 27.6 (6.4)
Mod-Vig Physical Activity (MET-hours/week)
Mean (SD) 27.6 (28.6) 27.6 (28.9) 33.0 (34.0) 0.03
Median (IQR) 19.5 (7.3–39.1) 19.4 (7.1–39.1) 24.4 (9.3–45.4)
Smoking History 0.28
Never 1118 (52.0) 1046 (51.5) 183 (56.3)
Former 913 (42.5) 874 (43.0) 129 (39.7)
Current 118 (5.5) 111 (5.5) 13 (4.0)
Alcohol Intake (g/day) 0.24
Never 511 (27.9) 477 (27.5) 81 (29.7)
#median2 665 (36.2) 618 (35.7) 106 (38.8)
.median 659 (35.9) 637 (36.8) 86 (31.5)
Vitamin Supplement Use 0.003
None 1263 (62.7) 177 (55.0)
Calcium 334 (16.6) 61 (18.9)
Vitamin D 259 (12.9) 43 (13.4)
Both 158 (7.9) 41 (12.7)
,0.0001
No 1792 (88.2) 225 (78.5)
#6 165 (8.1) 50 (12.3)
.6 76 (3.7) 30 (9.2)
Any Fracture Before BC Diagnosis (years) 0.27
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known risk factors for fractures are also relevant in breast cancer
patients, considering the paradoxical role of estrogens in
promoting carcinogenesis yet maintaining bone health.
In a cross-sectional analysis of one of the largest contemporary
cohorts of breast cancer patients, we describe history of
osteoporosis and fracture and the prevalence of risk factors for
fracture (age, race/ethnicity, body mass index (BMI), physical
activity, smoking, alcohol intake, and calcium and vitamin D
supplement use) before breast cancer diagnosis among initial AI
users. We also compare prevalence of bone health history in
postmenopausal AI users with postmenopausal TAM users. Lastly,
we examine associations of these fracture risk factors with prior
history of osteoporosis and fracture outcomes in AI users.
Materials and Methods
Study Population
The Pathways Study is a prospective study of 4,505 women with
newly diagnosed invasive breast cancer who are members of
Kaiser Permanente Northern California (KPNC), a large,
integrated health care delivery system covering the San Fran-
cisco-Oakland Bay Area, Sacramento, and surrounding counties.
Recruitment was from January 2006 to April 2013 through rapid
case ascertainment procedures designed to enroll women prior to
initiation of chemotherapy, as described elsewhere [17]. Eligibility
criteria included: KPNC female members at least 21 years of age;
had no previous history of malignancy other than non-melanoma
skin cancer; spoke English, Spanish, Cantonese, or Mandarin; and
resided within a 65-mile radius of a field interviewer. The mean
time from diagnosis to enrollment was 2.0 (60.7) months.
For this bone health sub-study, women were included if they
had at least one hormonal therapy prescription of an AI or TAM
that was indicated for treatment of their first primary breast
cancer. A total of 1,159 women who had no hormonal therapy, 27
women who initiated hormonal therapy after recurrence of their
original breast cancer, and 4 women who initiated hormonal
therapy after their second primary breast cancer were excluded.
The final study population consisted of 3,315 eligible women.
Based on complete hormonal therapy prescription data through
December 2013, 2,157 (65.1%) were initial AI users, and 1,158
(34.9%) were initial TAM users. For this analysis of baseline bone
health history, only the initial AI users were included. In selected
analyses, 325 postmenopausal women who received TAM as their
initial hormonal therapy drug were also included as a comparison
group to postmenopausal AI users (n = 2,033).
Clinicopathologic Characteristics
Clinical and diagnostic tumor characteristics were obtained
from the KPNC Cancer Registry approximately four months post-
diagnosis [18]. These included: stage at diagnosis, estrogen/
progesterone receptor (ER/PR) positivity, HER2/neu (Her2)
status, surgery type, and treatment received.
Self-reported Participant Information
The baseline interview was conducted at enrollment into the
cohort approximately two months post-diagnosis, and included
interviewer and self-administered questionnaires on sociodemo-
graphics, diet, physical activity, smoking, established breast cancer
risk factors, health history, and use of vitamin/mineral supple-
ments. Anthropometric measures were also obtained at baseline.
Information was collected on hysterectomy and oophorectomy
and associated dates of the surgery, and age or date of last period.
Menopause was defined as the absence of menses for 12
consecutive months or more relative to the date of the baseline
interview, or having a complete hysterectomy or oophorectomy of
both ovaries.
Physical activity was assessed using an activity frequency
questionnaire based on the validated Arizona Activity Frequency
Questionnaire (AAFQ) [19]. Activities in four main domains were
asked: household, recreational, transportation, and sedentary. Diet
was assessed using a 139-item modified version of the Block 2005
food frequency questionnaire (FFQ) (NutritionQuest, Berkeley,
CA). Alcohol consumption (beer, wine, and liquor), including
frequency and portion size, was obtained on the FFQ.
Pharmacy Data
Prescription drug data for nearly 100% of KPNC enrollees is
recorded in the KPNC pharmacy database, including drug name,
Table 1. Cont.
Overall Postmenopausal Only
AI (Initial Use) AI (Initial Use) TAM (Initial Use) p value1
n=2157 n=2033 n=325
n (%) n (%) n (%)
No 1695 (83.4) 272 (83.7)
#6 179 (8.8) 23 (7.1)
.6 159 (7.8) 30 (9.2)
0.13
No 1937 (95.3) 306 (94.2)
#6 60 (3.0) 11 (3.4)
.6 36 (1.8) 8 (2.5)
NOTE: Pharmacy data through December 31, 2013; Missing data for entire cohort: menopausal status (n = 9), BMI (n = 28), smoking (n = 13), alcohol (n = 552), vitamin
supplements (n = 37).
1 Logistic regression adjusted for age at breast cancer diagnosis as a continuous variable.
2 Median (overall) = 3.10 g/day, median (postmenopausal women) = 2.90 g/day.
3 Osteoporosis defined by ICD-9 code (733.00–733.09) or any prior bisphosphonate prescription.
4 Major fracture includes fracture of spine, humerus, wrist, or hip.
doi:10.1371/journal.pone.0111477.t001
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National Drug Code, dosage and therapeutic class; prescription
dates and cost; dispensing and refills; and prescribing physician,
thus minimizing recall bias [20]. The pharmacy database was
accessed to identify any outpatient prescriptions of AIs (anastro-
zole, letrozole, and exemestane) and TAM after breast cancer
diagnosis. Prescriptions of bisphosphonates (BP) any time before
breast cancer diagnosis were also captured. BPs are inhibitors of
bone resorption and commonly prescribed to treat osteoporosis
and other related conditions.
Prior Bone Outcomes
International Classification of Diseases, 9th edition (ICD-9)
outpatient and hospitalization diagnoses of bone outcomes were
obtained from the KPNC electronic medical record (EMR). These
diagnosis codes include: (1) osteoporosis (733.00–733.09); (2) any
prior fracture involving the neck, trunk, upper and lower
extremities (805, 807–815, 817–825, 827–829, excluding open
fractures, fractures involving spinal cord injury, fractures of the
face/skull, fingers and toes, and those associated with major
trauma); and (3) any major osteoporotic fracture of the spine,
humerus, wrist, or hip (805.0, 805.2, 805.4, 805.8, 812.0, 812.2,
813.4, 813.5, 820.0, 820.2, 820.8, excluding those associated with
major trauma) were ascertained as previously described [21].
Considering potential under-diagnosis or documentation of
osteoporosis by clinicians [22,23], we assumed that if a woman was
prescribed a BP prior to breast cancer diagnosis, and considering
Table 2. Baseline characteristics in relation to osteoporosis1 before breast cancer diagnosis (BC) in aromatase inhibitor (AI) users.
Osteoporosis Before
BC Diagnosis – Yes
Osteoporosis Before
BC Diagnosis – No OR2 95% CI2 p for trend
n=242 n=1915
n (%) n (%)
Age at BC Diagnosis (years) ,0.0001
,60 31 (12.8) 689 (36.0) Ref
60–69 95 (39.3) 796 (41.6) 2.43 (1.58, 3.72)
$70 116 (47.9) 430 (22.5) 5.65 (3.68, 8.69)
Race/Ethnicity –
White 182 (75.2) 1359 (71.0) Ref
African American 5 (2.1) 119 (6.2) 0.38 (0.15, 0.94)
Asian 30 (12.4) 191 (10.0) 1.82 (1.17, 2.81)
Hispanic 19 (7.9) 206 (10.8) 0.86 (0.52, 1.43)
Other 6 (2.5) 40 (2.1) 1.46 (0.60, 3.54)
BMI (kg/m2) ,0.0001
,25 114 (47.3) 528 (27.8) Ref
25–29.9 77 (32.0) 603 (31.8) 0.55 (0.40, 0.76)
$30 50 (20.8) 766 (40.4) 0.32 (0.22, 0.45)
Mod-Vig Physical Activity (MET-hours/week) –
Never 16 (6.7) 92 (4.8) Ref
#median3 102 (42.5) 915 (48.2) 0.92 (0.51, 1.67)
.median 122 (50.8) 893 (47.0) 1.25 (0.69, 2.27)
Smoking History –
Never 134 (55.4) 984 (51.6) Ref
Former 101 (41.7) 812 (42.6) 0.86 (0.65, 1.15)
Current 7 (2.9) 111 (5.8) 0.62 (0.28, 1.39)
Alcohol Intake (g/day) –
Never 77 (34.8) 434 (26.9) Ref
#median3 73 (33.0) 591 (36.6) 0.73 (0.51, 1.05)
.median 71 (32.1) 589 (36.5) 0.72 (0.50, 1.04)
Vitamin Supplement Use –
None 146 (60.8) 1202 (63.5) Ref
Calcium 40 (16.7) 311 (16.4) 1.08 (0.73, 1.58)
Vitamin D 34 (14.2) 235 (12.4) 1.06 (0.69, 1.63)
Both 20 (8.3) 145 (7.7) 1.03 (0.61, 1.74)
NOTE: Pharmacy data through December 31, 2013.
1 Osteoporosis defined by ICD-9 code (733.00–733.09) or any prior bisphosphonate prescription.
2 Logistic regression adjusted for age, race/ethnicity, menopausal status, and year of breast cancer diagnosis.
3 Median (physical activity) = 20.9 metabolic equivalent (MET)-hours/week; median (alcohol intake) = 3.1 g/day.
doi:10.1371/journal.pone.0111477.t002
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that BPs are usually indicated for clinical treatment of osteopo-
rosis, she was most likely diagnosed with the condition. Therefore,
we expanded our definition of osteoporosis to include any
prescription of BP before breast cancer diagnosis regardless of
whether or not an ICD-9 diagnosis code was present. Thus,
osteoporosis was defined as having any relevant ICD-9 diagnosis
code or any prior prescription of BP.
Statistical Analysis
Analyses of initial AI or TAM use in postmenopausal breast
cancer patients by select characteristics, including prior history of
osteoporosis and fracture, were conducted using logistic regression
with adjustment for age at breast cancer diagnosis as a continuous
variable.
In the overall initial AI user group, we calculated odds ratios
(OR) and 95% confidence intervals (CI) using logistic regression to
estimate the associations of lifestyle and clinical factors at breast
Table 3. Baseline characteristics in relation to any fracture before breast cancer (BC) diagnosis in aromatase inhibitor (AI) users.
Any Fracture Before
BC Diagnosis – Yes
Any fracture Before
BC Diagnosis – No OR1 95% CI1 p for trend
n=352 n=1805
n (%) n (%)
Age at BC Diagnosis (years) ,0.0001
,60 70 (19.9) 650 (36.0) Ref
60–69 143 (40.6) 748 (41.4) 1.76 (1.27, 2.43)
$70 139 (39.5) 407 (22.6) 3.13 (2.24, 4.37)
Race/Ethnicity –
White 268 (76.1) 1273 (70.5) Ref
African American 24 (6.8) 100 (5.5) 1.30 (0.81, 2.08)
Asian 17 (4.8) 204 (11.3) 0.50 (0.30, 0.84)
Hispanic 34 (9.7) 191 (10.6) 0.97 (0.66, 1.44)
Other 9 (2.6) 37 (2.1) 1.37 (0.65, 2.90)
BMI (kg/m2) 0.86
,25 93 (26.6) 549 (30.7) Ref
25–29.9 135 (38.6) 545 (30.5) 1.43 (1.06, 1.92)
$30 122 (34.9) 694 (38.8) 1.00 (0.74, 1.36)
Mod-Vig Physical Activity (MET-hours/week) –
Never 26 (7.5) 82 (4.6) Ref
#median2 164 (47.0) 853 (47.6) 0.83 (0.51, 1.35)
.median 159 (45.6) 856 (47.8) 0.84 (0.51, 1.37)
Smoking History –
Never 178 (50.7) 940 (52.3) Ref
Former 152 (43.3) 761 (42.3) 0.93 (0.73, 1.19)
Current 21 (6.0) 97 (5.4) 1.24 (0.75, 2.07)
Alcohol Intake (g/day) –
Never 89 (30.4) 422 (27.4) Ref
#median2 88 (30.0) 576 (37.4) 0.73 (0.52, 1.01)
.median 116 (39.6) 544 (35.3) 1.00 (0.73, 1.38)
Vitamin Supplement Use –
None 203 (58.8) 1145 (64.0) Ref
Calcium 60 (17.4) 291 (16.3) 1.21 (0.88, 1.68)
Vitamin D 49 (14.2) 220 (12.3) 1.12 (0.78, 1.61)




No 267 (75.9) 1648 (91.3) Ref
Yes 85 (24.2) 157 (8.7) 2.86 (2.10, 3.89)
NOTE: Pharmacy data through December 31, 2013.
1 Logistic regression adjusted for age, race/ethnicity, menopausal status, and year of breast cancer diagnosis.
2 Median (physical activity) = 20.9 metabolic equivalent (MET)-hours/week; median (alcohol intake) = 3.1 g/day.
doi:10.1371/journal.pone.0111477.t003
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cancer diagnosis with prior history of 1) osteoporosis, 2) any
fracture, and 3) any major osteoporotic fracture. All models were
adjusted for age, race/ethnicity, menopausal status, and year of
breast cancer diagnosis, and all p-values were two-tailed with a
significance level of 0.05. Analyses were repeated after excluding
those diagnosed with breast cancer before menopause. The results
were similar to those from the overall initial AI user group and
thus are not presented here.
All analyses were conducted in SAS version 9.3 (Cary, N.C.).
Ethics Statement
The study was approved by the KPNC institutional review
board.
Results
As shown in Table 1, the mean age at breast cancer diagnosis
among AI users was 64.4 years, with 2,033 (94.5%) initially
diagnosed after menopause and 118 (5.5%) before menopause. As
expected, the majority of the initial AI users were diagnosed with
early stage disease (AJCC stage I–III) (98.4%). The study cohort
was multi-ethnic, with 71.4% White, 10.4% Hispanic, 10.3%
Asian, 5.8% African American, and 2.1% other race/ethnicity.
The mean BMI at baseline was 29.0 kg/m2, with 31.8% being
overweight and 38.2% obese. The median (IQR) of moderate-
vigorous physical activity at baseline was 19.5 (7.3–39.1) metabolic
equivalent (MET)-hours/week. Over half of the patients were
never smokers at baseline (52.0%), 42.5% were former smokers,
and only 5.5% were current smokers. Alcohol intake was light at
baseline, with 27.9% being never drinkers, and among those who
drank, the median intake was 3.10 grams/day. Nearly two-thirds
of the patients did not take either calcium or vitamin D
supplements at baseline (63.2%), 16.5% took calcium, 12.6%
took vitamin D, and 7.7% took both supplements.
Among the initial AI users, 11.2% had a prior history of
osteoporosis, including 3.5% at 6 years or more before breast
cancer diagnosis, and 7.7% within 6 years (Table 1). 16.3% of the
patients had a prior history of any fracture, including 7.6% at 6
years or more before cancer diagnosis, and 8.7% within 6 years.
For major fractures of the spine, humerus, wrist, or hip, 4.6% had
a prior history of these fractures, including 1.7% at 6 years or
more before cancer diagnosis, and 2.9% within 6 years.
Among postmenopausal patients with HR-positive breast
cancer, the majority received AIs as their initial hormonal therapy
(n= 2,033, 86.2%), and 325 patients (n = 13.8%) received TAM as
their initial hormonal therapy. No apparent secular trend was
found in the use of AIs relative to TAM during the study period
(2005–2013). To explore whether bone health history or other
known risk factors for fractures might affect the choice of
hormonal therapy drugs, comparisons were conducted between
postmenopausal initial AI users and postmenopausal initial TAM
users. As shown among the postmenopausal women in Table 1,
compared to initial AI users, women on TAM were younger
(mean age 62.0 years vs. 65.2 years, p,0.0001), more likely to
have stage I disease (67.1% vs. 55.1%, p= 0.0003), less obese
(mean BMI 27.6 kg/m2 vs. 29.0 kg/m2, p = 0.0001), and more
physically active (median 19.4 MET-hours/week vs. 24.4 MET-
hours/week, p = 0.03). No differences in race/ethnicity, smoking
history, or alcohol intake were found between the two groups. For
bone health history prior to breast cancer diagnosis, although
initial TAM users were younger, they had a significantly higher
prevalence of prior osteoporosis than initial AI users (21.5% vs.
11.8%, p,0.0001), but a similar prevalence of any prior fracture
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4.8%, p= 0.13). Consistent with a higher prevalence of prior
osteoporosis compared with AI users, TAM users were more likely
to take calcium and/or vitamin D than AI users (45.0% vs. 37.3%,
p= 0.003).
In Tables 2–4, the associations of selected risk factors with prior
history of osteoporosis and fractures among overall initial AI users
are presented. In models adjusted for age, race/ethnicity,
menopausal status, and year of breast cancer diagnosis, older
age (60–69 y OR=2.43; 95% CI: 1.58, 3.72; $70 y OR=5.65;
95% CI: 3.68, 8.69; p for trend,0.0001) and being Asian
(OR=1.82; 95% CI: 1.17, 2.81) were associated with higher odds
of prior osteoporosis, whereas increasing BMI (overweight
OR=0.55; 95% CI: 0.40, 0.76; obese OR=0.32; 95% CI:
0.22, 0.45; p for trend,0.0001) and being African American
(OR=0.38; 95% CI: 0.15, 0.94) were associated with lower odds
(Table 2).
Associations of patient characteristics and lifestyle factors with
prior history of any fracture are given in Table 3. Older age was
associated with higher odds of any prior fracture (p for trend,
0.0001), whereas being Asian (OR=0.50; 95% CI: 0.30, 0.84) was
associated with lower odds of any prior fracture. In contrast to
associations with prior osteoporosis, no significant increasing BMI
trend was found, yet being overweight was associated with
increased odds of any prior fracture (OR=1.43; 95% CI: 1.06,
1.92). Finally, as expected, prior history of osteoporosis was
associated with increased odds of prior fracture (OR=2.86; 95%
CI: 2.10, 3.89). Associations of patient characteristics and lifestyle
factors with prior major fracture were largely consistent with any
prior fracture, but with wider CIs (Table 4). Unique to analyses of
major fracture, however, any moderate-vigorous physical activity
was associated with reduced odds of major fracture in the AI users
(#median 20.9 MET-hours/week OR=0.33 95% CI: 0.17, 0.64;
.median OR=0.36; 95% CI: 0.18, 0.70).
Discussion
In a large contemporary cohort of breast cancer survivors who
were initially treated with AIs, we found that 11.2% had a prior
history of osteoporosis, 16.3% any fracture, and 4.6% major
fracture before breast cancer diagnosis. Although the majority of
postmenopausal women were initially treated with AIs, a sizable
proportion (13.8%) was initially treated with TAM. Furthermore,
these TAM users had nearly twice the prevalence of prior
osteoporosis compared with initial AI users. Finally, the associa-
tions of selected risk factors with prior history of bone health
outcomes in breast cancer patients initially treated with AIs were
largely consistent with those expected from the healthy older
population [13,14].
To our knowledge, our observational study is the largest to date
to describe the use of AIs as primary hormonal therapy in
conjunction with prior bone morbidity. A previous study of 343
women with early-stage breast cancer about to initiate AI therapy
reported 22.2% with osteoporosis and 11.4% with any fracture
[16]. Another study of 497 breast cancer patients also at the onset
of AI therapy found 19.1% with non-vertebral fractures [15].
Compared with our prevalence findings of 11.2% osteoporosis and
16.3% any fracture, Servitja et al. reported a higher rate of
osteoporosis but a lower rate of fracture, whereas Bouvard et al.
reported a higher rate of fracture. While these studies were limited
by small sample size, they did collect baseline bone health
measures of BMD, spinal X-rays, and 25-hydroxyvitamin D [25-
(OH)D] concentrations. Our current analysis does not consider
these data, yet in future prospective analyses of fracture risk, we
will be incorporating BMD measures and 25(OH)D concentra-
tions around baseline entry into the cohort.
For postmenopausal women diagnosed with early stage, HR-
positive breast cancer, AIs have been shown to have superior
efficacy in lowering risk of recurrence compared with TAM, and
thus have become the preferable choice for this patient subgroup.
However, TAM remains a viable choice for initial hormonal
therapy for those who seek to avoid AIs’ musculoskeletal effects.
This is likely true for women deemed to have low risk of
recurrence but are susceptible to fractures, as suggested by our
results. In postmenopausal patients in our study, initial TAM users
were slightly younger than initial AI users, yet the former had
significantly higher prevalence of osteoporosis history. However,
initial TAM users were more likely to have stage I disease than
initial AI users, suggesting their risk of recurrence was lower. A
lower risk of recurrence coupled with a higher risk of fracture
might have influenced physicians and patients to favor TAM over
AIs as their first choice of initial hormonal therapy. This
speculation was further strengthened by the findings of higher
usage of calcium and/or vitamin D supplement and higher
physical activity in the initial TAM users than in the initial AI
users. As supplement use and physical activity were surveyed soon
after breast cancer diagnosis, we could not assess whether these
data represent exposure status before or after the diagnosis of
osteoporosis. Higher usage of supplements and being more
physically active might have been in response to being diagnosed
with osteoporosis (reverse causality). It is also interesting to note
that a small proportion of initial AI users were diagnosed with
breast cancer before menopause. Most likely those patients
experienced menopause due to chemotherapy or radiation therapy
and were subsequently eligible for AI therapy.
Among initial AI users, we identified several risk factors
associated with history of osteoporosis, including older age, Asian
race, and lower BMI. Older age was also associated with fracture
history and being physically active was associated with lower risk
of major prior fracture. These associations were in the same
direction as expected in a general healthy older population,
suggesting common mechanisms for osteoporosis and fracture
regardless of later breast cancer diagnosis. Although smoking and
alcohol consumption are risk factors for osteoporosis and fracture
in non-cancer patients, we did not find such associations in initial
AI users, possibly due to the small proportion (5.5%) of current
smokers in the study and light alcohol intake in the cohort (median
intake of 3.10 grams/day among drinkers). We also found that
Asian AI users had a higher risk of osteoporosis but lower risk of
prior fracture than Whites. This observation potentially reflects
known racial/ethnic differences of lower bone mineral density, yet
decreased fracture risk, in healthy Asians compared with Whites
[24,25,26].
When comparing our proportion of prior fracture to healthy
postmenopausal women at a similar age in the Women’s Health
Initiative (WHI) [27], initial postmenopausal AI users were
approximately two times less likely to have a history of fracture
(16.6% vs. 34.4%, p= 0.0039). The lower rate of prevalent
osteoporosis and fracture seen among breast cancer patients in our
study may be explained by the paradoxical association between
high BMD and breast cancer risk [28]. As estrogen plays a central
role in bone growth and maintenance, it also drives the
development of breast cancer. Therefore, at the time of diagnosis,
women with breast cancer may have had higher lifetime estrogen
exposure and associated BMD than non-cancer women at a
similar age, which may explain the lower prevalence of
osteoporosis and fracture among breast cancer patients seen in
our study.
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Our study was based on a large prospective breast cancer cohort
from one of the nation’s largest integrated healthcare delivery
systems where complete electronic medical records and pharmacy
information are available on all patients. This enabled us to
accurately assess bone health history through their health
insurance membership with Kaiser Permanente. Moreover, the
cohort was established in 2005, a time concurrent with the
widespread use of AIs. Our study was further strengthened by the
availability of extensive demographic and lifestyle information
collected at the time of diagnosis through in-person interviews.
Nevertheless, our study is not without limitations. Due to its
cross-sectional nature, we could not infer causality of the selected
risk factors for prevalent osteoporosis and fracture among breast
cancer patients. In addition, osteoporosis was potentially under-
diagnosed in our patient population. However, this is not a unique
challenge to this study. Clinicians vary in their use and coding of
the term osteoporosis such that it may be identified after BMD
testing, after a primary care visit, at the time of a specialty visit, at
the time of bisphosphonate initiation, or at the time of fracture.
Further, a diagnosis may not always mean that the T-score is in
the osteoporosis range, and a diagnosis could also be made in the
presence of a fragility fracture while BMD is only in the osteopenic
range. There have also been temporal changes in the frequency of
osteoporosis diagnosis [29], which may explain the greater
proportion of AI users with a priori osteoporosis diagnosis, as
AIs did not become the preferential choice of hormonal therapy
for postmenopausal breast cancer patients until the mid-2000’s.
To overcome this limitation, we classified patients with BP
treatment but without an ICD-9 diagnosis of osteoporosis as
osteoporotic. The results were similar when we relied only on
osteoporosis ICD-9 diagnosis. Furthermore, the prevalence of
prior spine fractures could have been underestimated due to
asymptomatic fractures not being coded by the physician, but for
our analyses, we considered spine fractures as clinically diagnosed.
Finally, given our access to electronic medical records on the
cohort, we estimate that only 35% had BMD measurements
before breast cancer diagnosis based on Current Procedural
Terminology (CPT) codes, thus precluding us from classifying
osteoporosis status based on BMD data for the entire cohort. To
note, the prevalence of prior BMD screening in our cohort is
greater than 16% reported in a small study of BMD screening
adherence among 342 breast cancer patients on AIs, and these
women were also members of an integrated health care system
[30].
To conclude, a small proportion of breast cancer patients
initially treated with AIs had a positive history of osteoporosis or
fracture before their cancer diagnosis. A history of osteoporosis
might influence the choice of initial hormonal therapy drug among
patients with low risk of recurrence. Risk factors for osteoporosis
and fracture before breast cancer diagnosis were similar to those
among healthy older women. Given that adverse effects on bone
health is a common comorbidity concern for many cancer
survivors [31], our findings may have wide clinical applicability
beyond breast cancer that emphasize the importance of full
consideration of prior bone health history before initiation of
cancer treatment.
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